Superoxide dismutase

Drug Profile

Superoxide dismutase

Alternative Names: SI 3501

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron Corporation; Seikagaku Corporation
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Osteoarthritis

Most Recent Events

  • 15 May 2001 Discontinued-Preclinical for Osteoarthritis in USA (Unknown route)
  • 12 Jun 1996 A preclinical study has been added to the Rheumatic disease pharmacodynamics section
  • 21 Aug 1995 Seikagaku Corporation is developing superoxide dismutase in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top